About Us


Syntimmune approaches areas of high unmet medical need in a unique way.

Syntimmune focuses on areas of science that are well understood and extensively researched. We seek new treatments that build on these areas of scientific consensus and broad applicability.

In the case of our lead drug candidate, SYNT001, both the cellular pathway and the specific molecular target have been studied extensively for more than 25 years, spearheaded by the groundbreaking research of the scientific team behind Syntimmune.

Syntimmune understands that creating real value comes from helping patients who are suffering with diseases for which current treatments are inadequate or nonexistent.



Jean-Paul Kress, M.D.

President & Chief Executive Officer

Jodie Morrison

Chief Operating Officer

Asti Goyal

Vice President, Corporate Strategy

Adam Hansard

Vice President, Business Operations

Stephanie Haller

Vice President, Clinical

Nicole Luosey

Vice President, Program Management

Leslie Stolz, Ph.D.

Vice President, Regulatory Strategy

Andreas Woppmann, Ph.D.

EVP, Technical Operations

Board of Directors

Seth Harrison, M.D.

Chairman of the Board, Syntimmune
Founder and Managing Partner at Apple Tree Partners

Burt Adelman, M.D.

Former Executive Vice President,
Research & Development at Dyax

Richard Blumberg, M.D.

Co-Founder, Syntimmune
Professor of Medicine at Harvard Medical School

Laurence Blumberg, M.D.

Co-Founder and Senior Advisor, Syntimmune

Sam Hall, Ph.D.

Principal at Apple Tree Partners

Aaron Kantoff

Principal at Apple Tree Partners

Jean-Paul Kress, M.D.

President and CEO, Syntimmune

Scientific Advisory Board

Richard Blumberg, M.D.

Chairman, Scientific Advisory Board
Harvard Medical School

Wayne Lencer, M.D.

Harvard Medical School

Inger Sandlie, Ph.D.

University of Oslo

Derry Roopenian, Ph.D.

The Jackson Laboratory

Alan Bitonti, Ph.D.

Senior Advisor


ATP logo-01